Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Etelcalcetide Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 916,238Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 4Parasbiv

    02 8Parsabiv

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Parasbiv

    Etelcalcetide

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Parasbiv

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Amgen

    Etelcalcetide

    Main Therapeutic Indication : Hormonal Disorders

    Currency : USD

    2020 Revenue in Millions : 716

    2019 Revenue in Millions : 630

    Growth (%) : 14

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Parsabiv

    Etelcalcetide

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Parsabiv

    Japan
    arrow
    2024 ACI Convention
    Not Confirmed

    Ono Pharma

    Etelcalcetide

    Main Therapeutic Indication : Hormonal Disorders

    Currency : USD

    2020 Revenue in Millions : 75

    2019 Revenue in Millions : 65

    Growth (%) : 16

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Parasbiv

    Etelcalcetide

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Parasbiv

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Amgen

    Etelcalcetide

    Main Therapeutic Indication : Hormonal Disorders

    Currency : USD

    2021 Revenue in Millions : 280

    2020 Revenue in Millions : 716

    Growth (%) : -61

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Parsabiv

    Etelcalcetide

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Parsabiv

    Japan
    arrow
    2024 ACI Convention
    Not Confirmed

    Ono Pharma

    Etelcalcetide

    Main Therapeutic Indication : Hormonal Disorders

    Currency : USD

    2021 Revenue in Millions : 73

    2020 Revenue in Millions : 72

    Growth (%) : 10

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Parsabiv

    Etelcalcetide

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Parsabiv

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Amgen

    Etelcalcetide

    Main Therapeutic Indication : Endocrinology

    Currency : USD

    2022 Revenue in Millions : 382

    2021 Revenue in Millions : 280

    Growth (%) : 36

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Parsabiv

    Etelcalcetide

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Parsabiv

    Japan
    arrow
    2024 ACI Convention
    Not Confirmed

    Ono Pharmaceuticals

    Etelcalcetide

    Main Therapeutic Indication : Endocrinology

    Currency : USD

    2022 Revenue in Millions : 65

    2021 Revenue in Millions : 73

    Growth (%) : -12

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Parsabiv

    Etelcalcetide

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Parsabiv

    Japan
    arrow
    2024 ACI Convention
    Not Confirmed

    Ono Pharmaceuticals

    Etelcalcetide

    Main Therapeutic Indication : Endocrinology

    Currency : USD

    2023 Revenue in Millions : 56

    2022 Revenue in Millions : 65

    Growth (%) : -1

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Parasbiv

    Etelcalcetide

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Parasbiv

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Amgen

    Etelcalcetide

    Main Therapeutic Indication : Hormonal Disorders

    Currency : USD

    2018 Revenue in Millions : 336

    2017 Revenue in Millions : 0

    Growth (%) : New Launch

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Parasbiv

    Etelcalcetide

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Parasbiv

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Amgen

    Etelcalcetide

    Main Therapeutic Indication : Hormonal Disorders

    Currency : USD

    2019 Revenue in Millions : 630

    2018 Revenue in Millions : 336

    Growth (%) : 88

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Parsabiv

    Etelcalcetide

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Parsabiv

    Japan
    arrow
    2024 ACI Convention
    Not Confirmed

    Ono Pharmaceuticals

    Etelcalcetide

    Main Therapeutic Indication : Hormonal Disorders

    Currency : USD

    2017 Revenue in Millions : 43

    2016 Revenue in Millions : Not Available

    Growth (%) : Not Available

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF